CIMA rejects Cephalon bid
Executive Summary
Cephalon's proposal to acquire CIMA at $26 per share does not represent a superior offer to CIMA's proposed merger with aaiPharma, CIMA says Sept. 2. Company received unsolicited takeover bid from Cephalon following announcement of proposed merger with aaiPharma; CIMA was prohibited from entering negotiations with Cephalon unless its board deemed the offer superior to merger plans (1"The Pink Sheet" Aug. 25, 2003, p. 17)...
You may also be interested in...
CIMA negotiations with Cephalon
CIMA reopens negotiations with Cephalon on a proposed merger. CIMA's board previously deemed a bid made by Cephalon of $26 per share insufficient to break CIMA's proposed merger with aaiPharma (1"The Pink Sheet" Sept. 8, 2003, In Brief). Cephalon has presumably increased its offer. CIMA and aaiPharma announced a proposed merger Aug. 5; Cephalon then made an unsolicited takeover bid...
FDA To Ramp Up ASCA Pilot In 2021
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: